Dasatinib 20/50/70/100 Teva 20 mg, 50 mg, 70 mg, 100 mg Tablet
PDF Leaflet Revision Date: 15 November 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of adults with Ph+ CML and Ph+ ALL.
Dosage (summary)
100 mg once daily for chronic phase CML; 70 mg twice daily for advanced phase CML or Ph+ ALL.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly
Pregnancy & Breastfeeding
Not recommended in pregnancy; contraindicated in breastfeeding.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- H2 antagonists
- Proton pump inhibitors
Contraindications
- Hypersensitivity to dasatinib
- Concomitant use of H2 antagonists or proton pump inhibitors
Common side effects
- Myelosuppression
- Fluid retention
- CNS bleeding
- QT prolongation
Counselling Points
- Take consistently with or without food
- Monitor for signs of bleeding or fluid retention
- Use contraception during treatment
Serious warnings
- Pulmonary arterial hypertension
- Severe dermatologic reactions
- Hepatitis B reactivation
Important Disclaimer
The Dasatinib 20/50/70/100 Teva 20 mg, 50 mg, 70 mg, 100 mg Tablet professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
